A Study of Anlotinib Combined With AK105 Injection in Subjects With Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Advanced Solid Tumor
A Randomized, Open-label , Multi-cohort, Multicenter, Phase II Study of Anlotinib Combined With AK105 Injection in Subjects With MSI-H or dMMR Advanced Solid Tumor
Sponsor: Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
This PHASE2 trial investigates MSI-H or dMMR Advanced Solid Tumors and is currently ongoing. Chia Tai Tianqing Pharmaceutical Group Co., Ltd. leads this study, which shows 6 recorded versions since 2020 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.
Status Flow
Change History
6 versions recorded-
Sep 2025 — Present [monthly]
Unknown PHASE2
-
Sep 2024 — Sep 2025 [monthly]
Unknown PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Unknown PHASE2
Status: Unknown Status → Unknown
-
Feb 2023 — Jul 2024 [monthly]
Unknown Status PHASE2
Status: Not Yet Recruiting → Unknown Status
-
Jan 2021 — Feb 2023 [monthly]
Not Yet Recruiting PHASE2
▶ Show 1 earlier version
-
Apr 2020 — Jan 2021 [monthly]
Not Yet Recruiting PHASE2
First recorded
Mar 2020
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
For direct contact, visit the study record on ClinicalTrials.gov .